Market Closed -
Nasdaq
04:00:00 2024-05-07 pm EDT
|
5-day change
|
1st Jan Change
|
330.5
USD
|
+0.15%
|
|
+0.09%
|
+73.43%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,350
|
3,553
|
6,296
|
7,431
|
7,031
|
12,389
|
-
|
-
|
Enterprise Value (EV)
1 |
1,168
|
3,368
|
6,112
|
7,151
|
6,772
|
11,880
|
11,572
|
11,187
|
P/E ratio
|
-20.5
x
|
-52.1
x
|
-686
x
|
36.1
x
|
49.5
x
|
62.3
x
|
53.3
x
|
44.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
31.4
x
|
52.4
x
|
26.5
x
|
15.2
x
|
9.63
x
|
13.3
x
|
10.9
x
|
9.03
x
|
EV / Revenue
|
27.2
x
|
49.7
x
|
25.8
x
|
14.6
x
|
9.27
x
|
12.8
x
|
10.2
x
|
8.16
x
|
EV / EBITDA
|
-24.9
x
|
-63
x
|
204
x
|
41.1
x
|
27.9
x
|
45.1
x
|
33
x
|
26.1
x
|
EV / FCF
|
-
|
-
|
2,353
x
|
-
|
40.9
x
|
52.5
x
|
53.8
x
|
35.2
x
|
FCF Yield
|
-
|
-
|
0.04%
|
-
|
2.44%
|
1.9%
|
1.86%
|
2.84%
|
Price to Book
|
7.17
x
|
15.9
x
|
25.9
x
|
14.6
x
|
10.5
x
|
13.1
x
|
9.68
x
|
7.62
x
|
Nbr of stocks (in thousands)
|
30,738
|
34,260
|
35,304
|
36,142
|
36,897
|
37,544
|
-
|
-
|
Reference price
2 |
43.92
|
103.7
|
178.3
|
205.6
|
190.6
|
330.0
|
330.0
|
330.0
|
Announcement Date
|
2/13/20
|
2/17/21
|
2/17/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
42.93
|
67.79
|
237.1
|
489.7
|
730.2
|
929.5
|
1,137
|
1,371
|
EBITDA
1 |
-46.86
|
-53.45
|
29.96
|
173.9
|
242.7
|
263.5
|
350.8
|
428.1
|
EBIT
1 |
-51.84
|
-65.66
|
-0.871
|
124.1
|
159.1
|
209.7
|
294.3
|
381
|
Operating Margin
|
-120.76%
|
-96.86%
|
-0.37%
|
25.35%
|
21.79%
|
22.56%
|
25.89%
|
27.78%
|
Earnings before Tax (EBT)
1 |
-51.05
|
-65.62
|
-8.835
|
120.8
|
174.3
|
246.2
|
310.6
|
387.7
|
Net income
1 |
-51.11
|
-65.7
|
-9.136
|
216
|
147.3
|
205.6
|
245.8
|
302.5
|
Net margin
|
-119.06%
|
-96.92%
|
-3.85%
|
44.1%
|
20.17%
|
22.12%
|
21.63%
|
22.06%
|
EPS
2 |
-2.140
|
-1.990
|
-0.2600
|
5.700
|
3.850
|
5.300
|
6.196
|
7.369
|
Free Cash Flow
1 |
-
|
-
|
2.597
|
-
|
165.5
|
226.1
|
215
|
318
|
FCF margin
|
-
|
-
|
1.1%
|
-
|
22.66%
|
24.32%
|
18.92%
|
23.19%
|
FCF Conversion (EBITDA)
|
-
|
-
|
8.67%
|
-
|
68.18%
|
85.8%
|
61.29%
|
74.29%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
112.34%
|
109.97%
|
87.46%
|
105.13%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/13/20
|
2/17/21
|
2/17/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
84.18
|
93.63
|
120.7
|
131.3
|
144
|
161.1
|
180.2
|
186
|
203
|
218.8
|
225.5
|
232.8
|
254.1
|
257.9
|
280.8
|
EBITDA
1 |
23.08
|
25.84
|
41.69
|
49.75
|
56.6
|
57.49
|
50.91
|
65.04
|
68.17
|
68.45
|
65.19
|
69.77
|
79.82
|
76.5
|
84.71
|
EBIT
1 |
13.98
|
15.37
|
29.58
|
36.76
|
42.42
|
39.81
|
32.37
|
43.62
|
43.28
|
42.41
|
49.95
|
54.9
|
64.25
|
61.48
|
69.88
|
Operating Margin
|
16.61%
|
16.42%
|
24.49%
|
27.99%
|
29.46%
|
24.72%
|
17.97%
|
23.45%
|
21.32%
|
19.38%
|
22.15%
|
23.59%
|
25.29%
|
23.84%
|
24.89%
|
Earnings before Tax (EBT)
1 |
13.05
|
14.72
|
26.34
|
35.12
|
44.65
|
40.74
|
33
|
45.08
|
55.46
|
50
|
59.25
|
63.15
|
76.65
|
69.7
|
76.5
|
Net income
1 |
12.94
|
14.52
|
25.56
|
35
|
140.9
|
39.12
|
28.86
|
34.99
|
44.3
|
55.35
|
44.45
|
47.4
|
57.45
|
57.59
|
62.35
|
Net margin
|
15.37%
|
15.51%
|
21.17%
|
26.65%
|
97.84%
|
24.29%
|
16.02%
|
18.81%
|
21.83%
|
25.29%
|
19.71%
|
20.36%
|
22.61%
|
22.34%
|
22.21%
|
EPS
2 |
0.3400
|
0.3900
|
0.6800
|
0.9200
|
3.710
|
1.030
|
0.7600
|
0.9200
|
1.160
|
1.440
|
1.145
|
1.248
|
1.496
|
1.481
|
1.586
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/17/22
|
5/9/22
|
8/8/22
|
11/7/22
|
2/16/23
|
5/8/23
|
8/7/23
|
11/6/23
|
2/15/24
|
5/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
182
|
186
|
184
|
280
|
259
|
509
|
817
|
1,202
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
2.6
|
-
|
165
|
226
|
215
|
318
|
ROE (net income / shareholders' equity)
|
-146%
|
-31.4%
|
-3.91%
|
57.4%
|
25%
|
22.6%
|
21.4%
|
19.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
43.6%
|
13.3%
|
9.17%
|
10.1%
|
10.5%
|
Assets
1 |
-
|
-
|
-
|
495.9
|
1,106
|
2,241
|
2,430
|
2,888
|
Book Value Per Share
2 |
6.130
|
6.530
|
6.890
|
14.10
|
18.10
|
25.20
|
34.10
|
43.30
|
Cash Flow per Share
2 |
-2.010
|
-2.150
|
-
|
3.110
|
5.130
|
5.480
|
1.120
|
6.450
|
Capex
1 |
-
|
-
|
-
|
25.1
|
30.6
|
38.4
|
45.3
|
47.5
|
Capex / Sales
|
-
|
-
|
-
|
5.13%
|
4.19%
|
4.13%
|
3.98%
|
3.46%
|
Announcement Date
|
2/13/20
|
2/17/21
|
2/17/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Average target price
310.4
USD Spread / Average Target -5.93% Consensus |
1st Jan change
|
Capi.
|
---|
| +73.43% | 12.38B | | -16.51% | 8.2B | | +16.03% | 7.3B | | +4.95% | 5.86B | | +13.07% | 5.32B | | +36.46% | 4.78B | | -18.88% | 4.16B | | -34.06% | 2.43B | | +1.73% | 2.05B | | +10.14% | 1.98B |
Medical Equipment
|